Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients.

Aparisi Gómez MP, Ponti F, Mercatelli D, Gasperini C, Napoli A, Battista G, Cariani S, Marchesini G, Bazzocchi A.

Nutrition. 2018 Oct 24;61:143-150. doi: 10.1016/j.nut.2018.10.023. [Epub ahead of print]

PMID:
30711863
2.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

PMID:
30587516
3.

Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Pia Sormani M, Ghezzi A.

Neurol Ther. 2018 Dec;7(2):391-393. doi: 10.1007/s40120-018-0116-x. Epub 2018 Nov 10. No abstract available.

4.

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3.

PMID:
30022464
5.

Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.

Galgani S, Prosperini L, Haggiag S, Tortorella C, Gasperini C.

J Neurol. 2018 Sep;265(9):2152-2153. doi: 10.1007/s00415-018-8976-7. Epub 2018 Jul 17. No abstract available.

PMID:
30019085
6.

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.

Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3.

PMID:
29970387
7.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

8.

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6.

PMID:
29875218
9.

Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O.

Brain. 2018 Jun 1;141(6):1665-1677. doi: 10.1093/brain/awy088.

10.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N; Jacqueline Palace on behalf of the MAGNIMS study group.

Nat Rev Neurol. 2018 Mar 20;14(4):213. doi: 10.1038/nrneurol.2018.39.

PMID:
29582852
11.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
12.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213. doi: 10.1038/nrneurol.2018.14. Epub 2018 Mar 9. Review. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213.

PMID:
29521337
13.

FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis.

Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, Ruggieri S, Capone A, Gasperini C, Matarese G, Battistini L, Borsellino G.

Sci Rep. 2018 Feb 27;8(1):3674. doi: 10.1038/s41598-018-21861-5.

14.

Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation.

Reale M, Costantini E, Di Nicola M, D'Angelo C, Franchi S, D'Aurora M, Di Bari M, Orlando V, Galizia S, Ruggieri S, Stuppia L, Gasperini C, Tata AM, Gatta V.

Sci Rep. 2018 Jan 22;8(1):1319. doi: 10.1038/s41598-018-19701-7.

15.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

16.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2018 Jan 1:1352458517751647. doi: 10.1177/1352458517751647. [Epub ahead of print]

PMID:
29327668
17.

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA.

Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.

PMID:
29275979
18.

Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis.

Amadio S, Parisi C, Piras E, Fabbrizio P, Apolloni S, Montilli C, Luchetti S, Ruggieri S, Gasperini C, Laghi-Pasini F, Battistini L, Volonté C.

Front Immunol. 2017 Nov 15;8:1529. doi: 10.3389/fimmu.2017.01529. eCollection 2017.

19.

Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.

Ruggieri S, Tortorella C, Gasperini C.

Expert Rev Neurother. 2017 Nov;17(11):1081-1089. doi: 10.1080/14737175.2017.1378098. Epub 2017 Sep 15. Review.

PMID:
28885860
20.

Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Neuroepidemiology. 2017;48(3-4):171-178. doi: 10.1159/000479515. Epub 2017 Aug 9.

PMID:
28793295
21.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

PLoS One. 2017 Aug 1;12(8):e0180651. doi: 10.1371/journal.pone.0180651. eCollection 2017.

22.

A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A.

Neurol Ther. 2017 Dec;6(2):161-173. doi: 10.1007/s40120-017-0079-3. Epub 2017 Jul 31. Review.

23.

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.

Tortorella C, Direnzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, D'Onghia M, Paolicelli D, Cuonzo FD, Gasperini C, Trojano M.

Mult Scler. 2018 Jul;24(8):1039-1045. doi: 10.1177/1352458517711774. Epub 2017 May 24. Erratum in: Mult Scler. 2018 Dec 3;:1352458518819093.

PMID:
28537100
24.

A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band.

Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco E, Santangelo M, Immovilli P, Gajofatto A, Calabrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo A, Frau J, Mariotto S, Gallina A, Gasperini C, Sola P; RIREMS group (Rising Italian Researchers in Multiple Sclerosis).

J Neurol. 2017 May;264(5):973-978. doi: 10.1007/s00415-017-8480-5. Epub 2017 Apr 5.

PMID:
28382419
25.

Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients.

Di Bari M, Reale M, Di Nicola M, Orlando V, Galizia S, Porfilio I, Costantini E, D'Angelo C, Ruggieri S, Biagioni S, Gasperini C, Tata AM.

Int J Mol Sci. 2016 Nov 30;17(12). pii: E2009.

26.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22.

PMID:
27878443
27.

Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Lazzarino G, Amorini AM, Petzold A, Gasperini C, Ruggieri S, Quartuccio ME, Lazzarino G, Di Stasio E, Tavazzi B.

Mol Neurobiol. 2017 Nov;54(9):7520-7533. doi: 10.1007/s12035-016-0257-9. Epub 2016 Nov 8.

PMID:
27826747
28.

Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.

Gasperini C, Hupperts R, Lycke J, Short C, McNeill M, Zhong J, Mehta LR.

J Neurol Sci. 2016 Nov 15;370:123-131. doi: 10.1016/j.jns.2016.08.052. Epub 2016 Aug 25.

29.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
30.

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9.

31.

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.

Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M.

J Neurol. 2016 Apr;263(4):751-9. doi: 10.1007/s00415-016-8049-8. Epub 2016 Feb 17.

32.

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group.

Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26. Review.

33.

Kounis syndrome: A concise review with focus on management.

Fassio F, Losappio L, Antolin-Amerigo D, Peveri S, Pala G, Preziosi D, Massaro I, Giuliani G, Gasperini C, Caminati M, Heffler E.

Eur J Intern Med. 2016 May;30:7-10. doi: 10.1016/j.ejim.2015.12.004. Epub 2016 Jan 12. Review.

PMID:
26795552
34.

The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis.

Di Mitri D, Sambucci M, Loiarro M, De Bardi M, Volpe E, Cencioni MT, Gasperini C, Centonze D, Sette C, Akbar AN, Borsellino G, Battistini L.

Immunology. 2015 Oct;146(2):251-63. doi: 10.1111/imm.12497. Epub 2015 Jul 6.

35.

Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System.

Bernocchi G, Fanizzi FP, De Pascali SA, Piccolini VM, Gasperini C, Insolia V, Bottone MG.

Toxics. 2015 Jun 19;3(2):224-248. doi: 10.3390/toxics3020224.

36.

FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients.

Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, Gasperini C, Centonze D, Barilá D, Battistini L, Volpe E.

Cell Death Dis. 2015 Jun 11;6:e1785. doi: 10.1038/cddis.2015.164. No abstract available.

37.

FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients.

Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, Gasperini C, Centonze D, Barilá D, Battistini L, Volpe E.

Cell Death Dis. 2015 May 7;6:e1741. doi: 10.1038/cddis.2015.100. Erratum in: Cell Death Dis. 2015;6:e1785.

38.

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.

Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.

Mult Scler. 2016 Feb;22(2):212-21. doi: 10.1177/1352458515581436. Epub 2015 Apr 28.

39.

Visual pathway neurodegeneration winged by mitochondrial dysfunction.

Petzold A, Nijland PG, Balk LJ, Amorini AM, Lazzarino G, Wattjes MP, Gasperini C, van der Valk P, Tavazzi B, Lazzarino G, van Horssen J.

Ann Clin Transl Neurol. 2015 Feb;2(2):140-50. doi: 10.1002/acn3.157. Epub 2014 Dec 17.

40.

T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.

Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, Gasperini C, Furlan R, Centonze D, Battistini L, Volpe E.

Clin Sci (Lond). 2015 Aug;129(4):291-303. doi: 10.1042/CS20140608.

PMID:
25700150
41.

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A.

Mult Scler. 2015 Nov;21(13):1713-22. doi: 10.1177/1352458515570768. Epub 2015 Feb 19.

PMID:
25698174
42.

Natalizumab discontinuation and disease restart in pregnancy: a case series.

De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C.

Acta Neurol Scand. 2015 May;131(5):336-40. doi: 10.1111/ane.12364. Epub 2015 Jan 18.

PMID:
25598313
43.

Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided Quality.

Di Battista G, Bertolotto A, Gasperini C, Ghezzi A, Maimone D, Solaro C.

Mult Scler Int. 2014;2014:752318. doi: 10.1155/2014/752318. Epub 2014 Aug 26.

44.

Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.

Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group.

Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54.

PMID:
25004826
45.

MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

Serana F, Imberti L, Amato MP, Comi G, Gasperini C, Ghezzi A, Martinelli V, Provinciali L, Rottoli MR, Sotgiu S, Stecchi S, Vecchio M, Zaffaroni M, Cordioli C, Capra R.

PLoS One. 2014 Apr 14;9(4):e94794. doi: 10.1371/journal.pone.0094794. eCollection 2014.

46.

Serum lactate as a novel potential biomarker in multiple sclerosis.

Amorini AM, Nociti V, Petzold A, Gasperini C, Quartuccio E, Lazzarino G, Di Pietro V, Belli A, Signoretti S, Vagnozzi R, Lazzarino G, Tavazzi B.

Biochim Biophys Acta. 2014 Jul;1842(7):1137-43. doi: 10.1016/j.bbadis.2014.04.005. Epub 2014 Apr 13.

47.

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.

Ruggieri S, Tortorella C, Gasperini C.

Ther Clin Risk Manag. 2014 Mar 27;10:229-39. doi: 10.2147/TCRM.S53285. eCollection 2014. Review.

48.

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.

Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, Nociti V, D'Onghia M, Lo Re V, Rodegher M, Solaro C, Gasperini C.

Mult Scler. 2014 Aug;20(9):1265-8. doi: 10.1177/1352458514521311. Epub 2014 Feb 10.

PMID:
24515732
49.

From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.

Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, Gasperini C.

Eur Neurol. 2014;71(5-6):233-41. doi: 10.1159/000356786. Epub 2014 Jan 25.

PMID:
24480868
50.

CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes.

Camperio C, Muscolini M, Volpe E, Di Mitri D, Mechelli R, Buscarinu MC, Ruggieri S, Piccolella E, Salvetti M, Gasperini C, Battistini L, Tuosto L.

Immunol Lett. 2014 Mar-Apr;158(1-2):134-42. doi: 10.1016/j.imlet.2013.12.020. Epub 2014 Jan 8.

PMID:
24412596

Supplemental Content

Loading ...
Support Center